Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

180 III. SUBSTANCES OF ABUSELing, L. H., Marchant, C., Buckley, N. A., Prior, M., & Irvine, R. J. (2001). Poisoningwith the recreational drug paramethoxyamphetamine (“death”). Med J Aust, 174,453–455.Lynskey, M., & Hall, W. (2000). The effects of adolescent cannabis use on educationalattainment: A review. Addiction, 95, 1621–1630.Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar,D., & Breier, A. (1996). NMDA receptor function and human cognition:The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14,301–307.Mamelak, M., Scharf, M. B., & Woods, M. (1986). Treatment of narcolepsy withgamma-hydroxybutyrate: A review of clinical and sleep laboratory findings. Sleep,9, 285–259.Marmor, J. B. (1998). Medical marijuana. West J Med, 168, 540–543.Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990). Delta-9-tetrahydrocannabinolshows antispastic and analgesic effects in a single case double-blindtrial. Eur Arch Psychiatry Clin Neurosci, 240, 1–4.McCabe, E. R., Layne, E. C., Sayler, D. F., Slusher, N., & Bessman, S. P. (1971). Synergyof ethanol and a natural soporific: Gamma hydroxybutyrate. Science, 171,404–406.McCann, U. D., Eligulashvili, W., & Ricaurte, G. A. (2000). (+/–) 3,4-Methylentdioxymethamphetamine(“Ecstasy”)-induced serotonin neurotoxicity: Clinicalstudies. Neuropsychobiology, 42, 11–16.McCann, U. D., & Ricaurte, G. (1991). Lasting neuropsychiatric sequelae of methylenedioxymethamphetamine(“Ecstasy”) in recreational users. J Clin Psychopharmacol,11, 302–305.McCann, U. D., & Ricaurte, G. (1993). Reinforcing subjective effects of 3,4-methylenedioxymethamphetamine(“Ecstasy”) may be separable from its neurotoxicactions: Clinical evidence. J Clin Psychopharmacol, 13, 214–217.McCann, U. D., Ridenour, A., Shaham, Y., & Ricaurte, G. A. (1994). Serotoninneurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA;“Ecstasy”): A controlled study in humans. Neuropsychopharmacology, 10, 129–138.McCann, U. D., Slate, S., & Ricaurte, G. (1996). Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA: “Ecstasy”). Drug Safety, 15, 107–115.McDowell, D., & Kleber, H. (1994). MDMA, its history and pharmacology. PsychiatrAnn, 24, 127–130.McDowell, D., & Spitz, H. (1999). Substance abuse: From principles to practice. NewYork: Brunner/Mazel.McDowell, D. M. (1998). Testimony to House Judiciary Committee. Available atwww.house.gov/judiciary/mcdo0615.htmMcKenna, D., & Peroutka, S. (1990). The neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine, “Ecstasy.” J Neurochem, 54, 14–22.Meyer, J. S., Greifenstein, F., & DeVault, M. (1959). A new drug causing symptoms ofsensory depravation. J Nerv Ment Dis, 129, 54–61.Moretti, R. J., Hassan, S. Z., Goodman, L. I., & Meltzer, H. Y. (1984). Comparison ofketamine and thiopental in healthy volunteers: Effects on mental status, mood,and personality. Anesth Analg, 63, 1087–1096.